乳腺癌是美国女性中第二常见的癌症，其标准治疗方法是手术结合辅助治疗。冷冻消融利用极冷的温度破坏肿瘤，同时保留潜在的肿瘤抗原，是手术切除的一种有前途的替代方案。它侵入性较小、美观、具有成本效益，并且能够促进远隔效应——针对潜在远处转移的免疫反应。然而，为了最大限度地发挥冷冻消融治疗生物学高风险乳腺癌的免疫学益处，可能需要与增强免疫激活的疗法（例如免疫检查点抑制剂（ICIs））相结合。这篇简短的评论描述了冷冻消融和 ICI 治疗的基本原理，并讨论了旨在改进这种方法以造福患者的策略和当前临床试验中的注意事项。版权所有 © 2023 Sardela de Miranda、Castro、Remmert、Singh、Layeequr Ra​​hman还有梅尔库斯。

Breast cancer is the second most common cancer among women in the United States in which the standard of care treatment is surgery with adjunctive therapy. Cryoablation, which destroys the tumor using extremely cold temperatures while preserving the potential tumor antigens, is a promising alternative to surgical resection. It is less invasive, cosmetically appeasing, cost-effective, and capable of contributing to the abscopal effect - the immune response targeting potential distant metastasis. However, to maximize the immunologic benefit of cryoablation in biologically high-risk breast cancers, combination with therapies that enhance immune activation, such as immune checkpoint inhibitors (ICIs) may be necessary. This mini review describes the fundamentals of cryoablation and treatment with ICIs, as well as discuss the caveats in both strategies and current clinical trials aimed to improve this approach to benefit patients.Copyright © 2023 Sardela de Miranda, Castro, Remmert, Singh, Layeequr Rahman and Melkus.